General description

Bleomycin is an antineoplastic agent that inhibits DNA metabolism and is used in the treatment of lymphomas and solid tumours.

<table>
<thead>
<tr>
<th>INN</th>
<th>Bleomycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATC codes</td>
<td>L01DC01</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
</tbody>
</table>
| EML status history | First added in 1979 (TRS 641) for Hodgkin lymphoma  
Added in 1979 (TRS 641) for Germ cell tumour of testis  
Added in 1979 (TRS 641) for Other specified malignant neoplasms of the ovary  
Added in 1979 (TRS 641) for Kaposi sarcoma of unspecified primary site  
Added in 1979 (TRS 641) for Unspecified malignant neoplasms of ill-defined or unspecified sites  
Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites |
| Wikipedia | Bleomycin |
| DrugBank | Bleomycin |

Recommendations

Section  Cytotoxic medicines

Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)

Indications

- Hodgkin lymphoma
- Kaposi sarcoma of unspecified primary site
- Germ cell tumour of testis
- Other specified malignant neoplasms of the ovary
- Unspecified malignant neoplasms of ill-defined or unspecified sites